{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:28:06Z","timestamp":1789954086890,"version":"4.0.1"},"reference-count":51,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Chronic hepatitis C (HCV) infection perturbs lipid and glucose metabolism. The influence of direct acting antiviral (DAA) treatment and ribavirin on these measures was evaluated. Furthermore, the effect of HCV cure on these parameters was assessed. Participants were allocated to one of three 12-week treatment groups: non-cirrhotic genotype 1a-paritaprevir\/ritonavir\/ombitasvir\/dasabuvir (PrOD) plus ribavirin; non-cirrhotic 1b-PrOD; compensated cirrhotic 1a or 1b-PrOD plus ribavirin. Fasting insulin, glucose, lipid and apolipoprotein measures were assessed at baseline, Treatment Weeks 4 and 12, and 12 and 24 weeks post-dosing. Twenty-three of 24 participants achieved SVR (PP= 23\/24, 96% SVR). Overall, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglyceride levels all increased in treatment and post-dosing. However, LDL-C levels decreased during treatment in ribavirin recipients. Fasting glucose, insulin, and HOMA-IR were unchanged during treatment and 12 weeks post-treatment. By 12 weeks post-treatment, controlled attenuation parameter (CAP) scores, a measure of steatosis, increased from baseline (mean 30.3 \u00b1 63.5, p = 0.05). This regimen was safe and highly effective and did not influence glucose metabolism. Ribavirin exposure may mitigate some on-treatment lipid changes. Further mechanistic studies are needed to understand how ribavirin impacts lipid pathways, as there could be therapeutic implications. The metabolic pathophysiology of increased CAP score with HCV treatment requires explanation.<\/jats:p>","DOI":"10.3390\/cells8030252","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T04:06:55Z","timestamp":1552882015000},"page":"252","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters"],"prefix":"10.3390","volume":"8","author":[{"given":"Mary-Anne","family":"Doyle","sequence":"first","affiliation":[{"name":"Division of Endocrinology &amp; Metabolism, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"},{"name":"Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrissi","family":"Galanakis","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Mulvihill","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada"},{"name":"University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Crawley","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-3499","authenticated-orcid":false,"given":"Curtis L.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada"},{"name":"Division of Infectious Diseases, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1093\/cid\/cis361","article-title":"Global burden of hepatitis C: Considerations for healthcare providers in the United States","volume":"55","author":"Averhoff","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3748\/wjg.v16.i18.2265","article-title":"Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection","volume":"16","author":"Hung","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/00007890-200109270-00015","article-title":"Posttransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality","volume":"72","author":"Baid","year":"2001","journal-title":"Transplantation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1111\/j.1572-0241.2006.00835.x","article-title":"Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients","volume":"101","author":"Taura","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/599371","article-title":"Hepatitis C virus infection and the risk of coronary disease","volume":"49","author":"Butt","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jhep.2009.07.008","article-title":"Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin","volume":"51","author":"Grasso","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jhep.2007.07.026","article-title":"Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3","volume":"48","author":"Poustchi","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2337\/dc11-1837","article-title":"Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action","volume":"35","author":"Brandman","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3350\/cmh.2014.20.1.38","article-title":"The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients","volume":"20","author":"Jung","year":"2014","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.2337\/dc06-0456","article-title":"Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection","volume":"29","author":"Simo","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1136\/gutjnl-2011-300749","article-title":"Insulin resistance and response to telaprevir plus peginterferon alpha and ribavirin in treatment-naive patients infected with HCV genotype 1","volume":"61","author":"Serfaty","year":"2012","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/v5051292","article-title":"Hepatitis C virus, cholesterol and lipoproteins\u2014impact for the viral life cycle and pathogenesis of liver disease","volume":"5","author":"Felmlee","year":"2013","journal-title":"Viruses"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1073\/pnas.96.22.12766","article-title":"Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor","volume":"96","author":"Agnello","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jhep.2008.03.016","article-title":"Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study","volume":"49","author":"Dai","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/j.1572-0241.2003.07402.x","article-title":"Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis","volume":"98","author":"Petit","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-2893.2005.00655.x","article-title":"Serum lipid pattern in chronic hepatitis C: Histological and virological correlations","volume":"13","author":"Siagris","year":"2006","journal-title":"J. Viral. Hepat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1440-1746.2007.04911.x","article-title":"Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C","volume":"23","author":"Economou","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.23219","article-title":"Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-up","volume":"50","author":"Corey","year":"2009","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1872-034X.2008.00439.x","article-title":"Treatment of hepatitis C virus with peg-interferon and ribavirin combination therapy significantly affects lipid metabolism","volume":"39","author":"Tada","year":"2009","journal-title":"Hepatol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1136\/gut.2010.219089","article-title":"Danoprevir, an HCV NS3\/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C","volume":"59","author":"Moucari","year":"2010","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.27424","article-title":"Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients","volume":"61","author":"Meissner","year":"2015","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.4254\/wjh.v8.i35.1557","article-title":"Hepatitis C eradication with sofosbuvir leads to significant metabolic changes","volume":"8","author":"Morales","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.14218\/JCTH.2018.00007","article-title":"Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era","volume":"6","author":"Mathur","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1097\/QAD.0b013e32835612ce","article-title":"Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV\/hepatitis C virus-coinfected patients","volume":"26","author":"Hull","year":"2012","journal-title":"Aids"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/hep.22748","article-title":"Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C","volume":"49","author":"Lucidarme","year":"2009","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1016\/j.ijid.2012.02.004","article-title":"The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance","volume":"16","author":"Yu","year":"2012","journal-title":"Int. J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0168-8278(05)80631-2","article-title":"Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population","volume":"21","author":"Allison","year":"1994","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1572-0241.2007.01181.x","article-title":"Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: An epidemiological link with virological implication","volume":"102","author":"Huang","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0002-9440(10)63408-6","article-title":"Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3","volume":"165","author":"Kawaguchi","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jhep.2008.08.006","article-title":"Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis","volume":"49","author":"White","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0168-8227(90)90093-9","article-title":"Alterations of glucose metabolism in chronic liver disease","volume":"8","author":"Gentile","year":"1990","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_35","first-page":"749","article-title":"Glucose intolerance in liver cirrhosis: Role of hepatic and non-hepatic influences","volume":"32","author":"Muller","year":"1994","journal-title":"Eur. J. Clin. Chem. Clin. Biochem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage","volume":"31","author":"Fattovich","year":"2000","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/bmj.39457.828287.47","article-title":"Artificially low HbA1c associated with treatment with ribavirin","volume":"336","author":"Robertson","year":"2008","journal-title":"BMJ"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc17-0485","article-title":"Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus","volume":"40","author":"Hum","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"462e1-3","DOI":"10.1016\/j.cmi.2015.12.030","article-title":"Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents","volume":"22","author":"Pavone","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.tim.2015.07.007","article-title":"Roles of Lipoproteins and Apolipoproteins in Particle Formation of Hepatitis C Virus","volume":"23","author":"Fukuhara","year":"2015","journal-title":"Trends Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/14789450.2017.1344102","article-title":"Hepatitis C virus-apolipoprotein interactions: Molecular mechanisms and clinical impact","volume":"14","author":"Crouchet","year":"2017","journal-title":"Expert Rev. Proteom."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1128\/JVI.07222-11","article-title":"Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate","volume":"86","author":"Jiang","year":"2012","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"12680","DOI":"10.1128\/JVI.01476-09","article-title":"Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles","volume":"83","author":"Jiang","year":"2009","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.virol.2009.08.037","article-title":"Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor","volume":"394","author":"Owen","year":"2009","journal-title":"Virology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9632","DOI":"10.1128\/JVI.01353-16","article-title":"Neglected but Important Role of Apolipoprotein E Exchange in Hepatitis C Virus Infection","volume":"90","author":"Yang","year":"2016","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/gut.2010.211292","article-title":"Hepatitis C virus production requires apolipoprotein A-I and affects its association with nascent low-density lipoproteins","volume":"60","author":"Mancone","year":"2011","journal-title":"Gut"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Icard, V., Diaz, O., Scholtes, C., Perrin-Cocon, L., Ramiere, C., Bartenschlager, R., Penin, F., Lotteau, V., and Andre, P. (2009). Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004233"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0168-8278(00)00036-2","article-title":"Hepatitis C virus induced hypobetalipoproteinemia: A possible mechanism for steatosis in chronic hepatitis C","volume":"34","author":"Serfaty","year":"2001","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Maillard, P., Walic, M., Meuleman, P., Roohvand, F., Huby, T., Le Goff, W., Leroux-Roels, G., Pecheur, E.I., and Budkowska, A. (2011). Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0026637"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12072-014-9572-2","article-title":"Assessment of the features of serum apolipoprotein profiles in chronic HCV infection: Difference between HCV genotypes 1b and 2","volume":"8","author":"Seki","year":"2014","journal-title":"Hepatol. Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/gutjnl-2011-301798","article-title":"Very low-density lipoprotein\/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III","volume":"62","author":"Sun","year":"2013","journal-title":"Gut"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/3\/252\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:38:19Z","timestamp":1760186299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/3\/252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["cells8030252"],"URL":"https:\/\/doi.org\/10.3390\/cells8030252","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,15]]}}}